Functional characterization and pharmacochaperone rescue of a novel SLC6A1 variant associated with developmental epileptic encephalopathies
Abstract
Mutations in SLC6A1 , encoding the γ-aminobutyric acid (GABA) transporter 1 (GAT-1), are associated with a spectrum of neurodevelopmental disorders, including epilepsy syndromes, intellectual disability (ID), and autism. An important question is whether the impact of these mutations can be predicted at scale using artificial intelligence (AI), and how such predictions correlate with experimental findings. In this study, AI was explored as a predictive tool, not as a replacement for data collected experimentally. We reported clinical presentations including seizures and EEG features, autism related phenotypes and motor skills in a novel variant c.1069G > A (p.Ala357Thr, A357T) in two siblings. We used both AI tools and experimental approaches to characterize this novel mutation in the SLC6A1 gene and compared it with another variant in the same amino acid, c.1070 C > T (p.Ala357Val, A357V). Both AI and experimental approaches indicate that the GAT-1(A357T) and (A357V) mutations destabilize the global protein conformation and have increased localization inside the endoplasmic reticulum (ER). Additionally, the presence of the mutant GAT-1 made the wildtype GAT-1 less mature. Radioactive ³ H-labeled GABA uptake assay indicated the mutation drastically reduced the function of the GAT-1(A357T) compared with the wildtype across cell types and pharmacochaperones such as 4-phenylbutyrate rescued the trafficking and function of the mutant GAT-1. Common and differential clinical phenotypes were identified in the siblings carrying the same variant. Mutant GAT-1 caused increased ER retention and impaired the trafficking of wild type GAT-1. PBA treatment rescued the mutant GAT-1 protein expression and GABA uptake function. AI-assisted in silico protein structural modeling and experimental approaches consistently suggest that the A357T and A357V variants destabilize global GAT-1 protein conformation. AI-assisted protein stability predictions provide supportive structural insight but cannot replace experimental assessment of GAT-1 expression and function.
Related
- Caregiver perceptions of telemedicine in developmental and epileptic encephalopathies: a nationwide Spanish survey
- Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care.
- Beyond seizures: the hidden burden of developmental epileptic encephalopathies
- Clinic-to-Mechanism: Unraveling in-depth molecular dysfunctions caused by a GluN2B C-Terminal deletion in developmental and epileptic encephalopathies
- Precision Therapeutics for Monogenic Epilepsies: From Molecular Mechanisms to Disease Modification in Developmental and Epileptic Encephalopathies and Neurodevelopmental Disorders with Epilepsy
BibTeX
@article{song2026functional,
title = {{Functional characterization and pharmacochaperone rescue of a novel SLC6A1 variant associated with developmental epileptic encephalopathies}},
author = {Ziang Debbie Song and Melissa B. DeLeeuw and Despoina Mandelenaki and Wangzhen Shen and Ria S. Eda and Juexin Wang and Jing-Qiong Kang},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-72601-z},
url = {https://www.nature.com/articles/s41598-026-72601-z},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Functional characterization and pharmacochaperone rescue of a novel SLC6A1 variant associated with developmental epileptic encephalopathies
AU - Ziang Debbie Song
AU - Melissa B. DeLeeuw
AU - Despoina Mandelenaki
AU - Wangzhen Shen
AU - Ria S. Eda
AU - Juexin Wang
AU - Jing-Qiong Kang
PY - 2026
DA - 2026/10/07
JO - Scientific Reports
DO - 10.1038/s41598-026-72601-z
UR - https://www.nature.com/articles/s41598-026-72601-z
AB - Mutations in SLC6A1 , encoding the γ-aminobutyric acid (GABA) transporter 1 (GAT-1), are associated with a spectrum of neurodevelopmental disorders, including epilepsy syndromes, intellectual disability (ID), and autism. An important question is whether the impact of these mutations can be predicted at scale using artificial intelligence (AI), and how such predictions correlate with experimental findings. In this study, AI was explored as a predictive tool, not as a replacement for data collected experimentally. We reported clinical presentations including seizures and EEG features, autism related phenotypes and motor skills in a novel variant c.1069G > A (p.Ala357Thr, A357T) in two siblings. We used both AI tools and experimental approaches to characterize this novel mutation in the SLC6A1 gene and compared it with another variant in the same amino acid, c.1070 C > T (p.Ala357Val, A357V). Both AI and experimental approaches indicate that the GAT-1(A357T) and (A357V) mutations destabilize the global protein conformation and have increased localization inside the endoplasmic reticulum (ER). Additionally, the presence of the mutant GAT-1 made the wildtype GAT-1 less mature. Radioactive ³ H-labeled GABA uptake assay indicated the mutation drastically reduced the function of the GAT-1(A357T) compared with the wildtype across cell types and pharmacochaperones such as 4-phenylbutyrate rescued the trafficking and function of the mutant GAT-1. Common and differential clinical phenotypes were identified in the siblings carrying the same variant. Mutant GAT-1 caused increased ER retention and impaired the trafficking of wild type GAT-1. PBA treatment rescued the mutant GAT-1 protein expression and GABA uptake function. AI-assisted in silico protein structural modeling and experimental approaches consistently suggest that the A357T and A357V variants destabilize global GAT-1 protein conformation. AI-assisted protein stability predictions provide supportive structural insight but cannot replace experimental assessment of GAT-1 expression and function.
SN - 2045-2322
ER -